Notes on human behavioural pharmacotoxicology.
1. After 30 years of psychopharmacological therapy we are able to identify some aspects which can be referred to a "collateral behavioural effect". The apparent rarity of this depends on the facility of confusing behavioural modifications (often sine materia), with patological ones (normally of a physical nature). 2. Memory, learning, the ability of evoking, problems regarding reality, paradoxical reactions, "makefobic" behaviour, passivity and social and behavioural withdrawal, form part of the Human Behavioural Pharmacotoxicology. 3. This ought to deserve greater attention on the part both of research workers and health authorities.
D014151:Anti-Anxiety Agents / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001569:Benzodiazepines; D003692:Delayed-Action Preparations; D006801:Humans; D008094:Lithium / Q000009:adverse effects; D016651:Lithium Carbonate; D001523:Mental Disorders / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000209:etiology*
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D011619:Psychotropic Drugs; D001569:Benzodiazepines; D016651:Lithium Carbonate; D008094:Lithium